Insights & Analysis
Market analysis, trading insights, educational content, and deep dives into the companies and sectors that matter to retail investors.
The Stock Sleuth
"Do the math..."Where our two current calls stand now: Eli Lilly’s $2.8B ATAI deal validates the psychedelic-medicine category and leaves Compass Pathways the premier independent name — while a wave of buy-equivalent Wall Street initiations puts SpaceX’s consensus target near $244, roughly double its price.
You've watched crypto-exposed stocks run up 500% and give it all back. Here's the structural reason almost no one is explaining correctly — a guest column by crypto M&A attorney Thomas Gaffney, with analysis from WSPS.
More on the way
Subscribe to our newsletter to get new posts in your inbox the moment they publish.
"Our recommendations deliver, and consistently beat the street. Do the math."
Follow @wsprofitsearch